Overview
Findings suggest that while ERBB2-mutated cases frequently present with low HER2 expression, they represent a actionable subgroup for HER2-targeted antibody-drug conjugates and immunotherapies.
This study analyzes 69 metastatic endometrial cancer samples, identifying ERBB2 (HER2) pathogenic mutations as defining a distinct, often non-amplified subgroup (84% of cases) characterized by low HER2 expression (0/1+ in 66% of cases) and high co-occurrence with MSI-High/POLE subtypes. Findings suggest that while ERBB2-mutated cases frequently present with low HER2 expression, they represent a actionable subgroup for HER2-targeted antibody-drug conjugates and immunotherapies.